Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
André J. Scheen. (2023) Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update. Expert Opinion on Drug Metabolism & Toxicology 19:8, pages 543-553.
Read now
Read now
Anthony H Barnett. (2015) Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation. Expert Opinion on Drug Safety 14:1, pages 149-159.
Read now
Read now
André J Scheen. (2015) A review of gliptins for 2014. Expert Opinion on Pharmacotherapy 16:1, pages 43-62.
Read now
Read now
André J Scheen. (2014) Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 839-857.
Read now
Read now
André J Scheen. (2013) Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opinion on Drug Metabolism & Toxicology 9:5, pages 529-550.
Read now
Read now
André J Scheen. (2013)
Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. Expert Opinion on Drug Metabolism & Toxicology 9:3, pages 363-377.
Read now
Read now
André J Scheen. (2013) Efficacy and safety of Jentadueto® (linagliptin plus metformin). Expert Opinion on Drug Safety 12:2, pages 275-289.
Read now
Read now
Ronnie Aronson. (2012) Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea. Expert Opinion on Pharmacotherapy 13:10, pages 1535-1539.
Read now
Read now
André J Scheen. (2012)
Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opinion on Drug Metabolism & Toxicology 8:3, pages 383-394.
Read now
Read now
André J Scheen. (2012) A review of gliptins in 2011. Expert Opinion on Pharmacotherapy 13:1, pages 81-99.
Read now
Read now
Articles from other publishers (16)
Athanasia Papazafiropoulou & Andreas Melidonis. (2019) Antidiabetic agents in patients with hepatic impairment. World Journal of Meta-Analysis 7:8, pages 380-388.
Crossref
Crossref
A.J. Scheen. (2019) Études cardiovasculaires chez le patient diabétique de type 2 à risque : conclusions et impact des essais publiés en 2017-2018. Médecine des Maladies Métaboliques 13, pages S10-S24.
Crossref
Crossref
Ruben Vardanyan. 2017. Piperidine-Based Drug Discovery. Piperidine-Based Drug Discovery
127
146
.
Cholleti Vijay Kumar, Pasula Aparna, Pavan Kumar Vasa, Y. Ravindra Kumar & Nitin Haridas Dhekale. (2016) A New and Enantioselective Chromatographic Method for Linagliptin on Amylose Coated Chiral Stationary Phase. American Journal of Analytical Chemistry 07:07, pages 556-567.
Crossref
Crossref
Julio Rosenstock, Nikolaus Marx, Dietmar Neubacher, Thomas Seck, Sanjay Patel, Hans-Juergen Woerle & Odd Erik Johansen. (2015) Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology 14:1.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
Crossref
André J. Scheen. (2014) Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes. Clinical Pharmacokinetics 54:1, pages 1-21.
Crossref
Crossref
André J. Scheen. (2014) Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus. Clinical Pharmacokinetics 53:9, pages 773-785.
Crossref
Crossref
Erika Paniago Guedes, Alexandre Hohl, Thais Gomes de Melo & Felipe Lauand. (2013) Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment. Diabetology & Metabolic Syndrome 5:1.
Crossref
Crossref
André J. Scheen. (2013) GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?. Annales d'Endocrinologie 74:5-6, pages 515-522.
Crossref
Crossref
Sang Ah Lee. (2013) DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes. The Journal of Korean Diabetes 14:3, pages 128.
Crossref
Crossref
Chrysi Koliaki & John Doupis. (2012) Linagliptin/Metformin Fixed-Dose Combination Treatment: A Dual Attack to Type 2 Diabetes Pathophysiology. Advances in Therapy 29:12, pages 993-1004.
Crossref
Crossref
Dilani D. De Silva, Sylvie Rapior, Kevin D. Hyde & Ali H. Bahkali. (2012) Medicinal mushrooms in prevention and control of diabetes mellitus. Fungal Diversity 56:1, pages 1-29.
Crossref
Crossref
Janet B. McGill. (2012) Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials. Therapeutic Advances in Endocrinology and Metabolism 3:4, pages 113-124.
Crossref
Crossref
A.J. Scheen. (2012) DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials. Diabetes & Metabolism 38:2, pages 89-101.
Crossref
Crossref
William T. Cefalu. (2012) Evolving Treatment Strategies for the Management of Type 2 Diabetes. The American Journal of the Medical Sciences 343:1, pages 21-26.
Crossref
Crossref